Psychedelic Therapy Scrutinized by FDA Advisory Committee?
JAMA · 24.09.2024 · 332 (12) · 963
DOI: 10.1001/jama.2024.13370 ↗Kurz gefasst
Editorial in der Zeitschrift JAMA, erschienen am 24.09.2024. Verfasst von Mason Marks. Beteiligte Einrichtung: Florida State University College of Law, Tallahassee. Hauptthemen laut MEDLINE: Advisory Committees, Hallucinogens, United States Food and Drug Administration, N-Methyl-3,4-methylenedioxyamphetamine. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint analyzes the Psychopharmacologic Drugs Advisory Committee’s decisions regarding 3,4-methylenedioxymethamphetamine–assisted therapy and what they mean for psychedelic research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Florida State University College of Law, Tallahassee.
- Project on Psychedelics Law and Regulation (POPLAR), Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Cambridge, Massachusetts.
Zitieren
APA
Marks, M. (2024). Psychedelic Therapy Scrutinized by FDA Advisory Committee?. JAMA, 332(12), 963. https://doi.org/10.1001/jama.2024.13370
Vancouver
Marks M. Psychedelic Therapy Scrutinized by FDA Advisory Committee?. JAMA. 2024;332(12):963. doi:10.1001/jama.2024.13370
BibTeX
@article{Marks2024,
author = {Marks, Mason},
title = {Psychedelic Therapy Scrutinized by FDA Advisory Committee?},
journal = {JAMA},
year = {2024},
volume = {332},
number = {12},
pages = {963},
doi = {10.1001/jama.2024.13370}
}
EUVIMED